Burning Rock’s minimal residual disease (MRD) product supports advancement in early-stage non-small cell lung cancer treatment, with results published in the Cancer Cell

Burning Rock Biotech Limited is delighted to announce that our personalized Minimal Residual Disease product, CanCatch®, was enrolled in a prospective observational study.